Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma

Sponsor
AHS Cancer Control Alberta
Study ID
NCT04107103
Phase
PHASE2
Status
Completed

Conditions

  • SCCHN

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Combination Product: Nivolumab with Pemetrexed — DRUG
    Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.

Study Details

The purpose of this study is to find out what effects the combination of Nivolumab and Pemetrexed has on you and your cancer. The safety of this combination and the effectiveness of this treatment will be studied.

Key Dates

Start date
Mar 19, 2020
Status verified
Jun 2024
Primary completion
Apr 14, 2023
Completion
Apr 28, 2023

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    A single-arm combining nivolumab with pemetrexed

Primary Outcome Measure

Feasibility [ Time Frame: 1 year after enrollment of last participant ]

Related Studies